drugset
drugset / Trial / NCT02440828

Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia

NCT02440828 ↗

Phase 4 Completed 80 enrolled Erasmus Medical Center Chiesi Farmaceutici S.p.A. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the addition of tobramycin inhalation treatment to standard intravenous therapy in the treatment of ventilator associated pneumonia.

Timeline

Start
2015-03
Primary completion
2020-03-01
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 300 mg Inhaled

Indications

No indication recorded.